Combining technology and methods for the imaging of large-scale neural activity in a naturally behaving subject, Inscopix is tackling the development of a new paradigm better to understand the brain and its diseases. The effort has been to enable means to relate causal neural circuit dynamics to corresponding behavior. The firm's flagship product - nVista HD- Inscopix is beingmade available to neuroscientists across the world, empowering them to gather unprecedented data and to make new scientific discoveries. With strategic collaborators and partners, Inscopix is also developing in vivo neuropsychiatric disease assays and stands on the brink of making fundamental breakthroughs on treatments for brain diseases such as autism and schizophrenia. Inscopix's core technology and methods for in vivo brain imaging spawned out of almost a decade of interdisciplinary research conducted by Inscopix's founding team at Stanford University, and was first reported in Nature Methods and Nature Medicine (cover story). At the 2012 Society for Neuroscience Meeting, Inscopix launched nVista HD, an end-to-end solution that permits neuroscientists to stream live, high-definition videos of large-scale neural activity from the brain of an awake, naturally behaving mouse. In November 2022 it was anounced that Bruker had acquired Inscopix for an undisclosed amount
